# Phase II Umbrella Study Directed by Next Generation Sequencing

> **NCT03574402** · PHASE2 · UNKNOWN · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 400 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Avitinib Maleate
- **DRUG:** Afatinib
- **DRUG:** Crizotinib
- **DRUG:** X-396
- **DRUG:** Chidamide
- **DRUG:** Pyrotinib Maleate
- **DRUG:** AZD3759
- **DRUG:** Pirotinib
- **DRUG:** Nimotuzumab
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin
- **DRUG:** Sintilimab
- **DRUG:** Gemcitabine
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT03574402
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-09
- **Primary completion:** 2022-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2022-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03574402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03574402, "Phase II Umbrella Study Directed by Next Generation Sequencing". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03574402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*